激光生物学报, 2017, 26 (6): 534, 网络出版: 2018-01-10  

GIP受体激动剂类药物筛选模型的构建

Construction of Screening Model for GIP Receptor Agonists
作者单位
1 湖南农业大学园艺园林学院, 湖南 长沙 410128
2 国家中医药管理局亚健康干预技术实验室, 湖南 长沙 410128
3 湖南农业大学食品科学技术学院, 湖南 长沙 410128
摘要
目的: GIP受体激动剂类药物筛选模型的构建。方法: GIP受体激动剂能刺激胰岛素分泌, 可作为治疗Ⅱ型糖尿病的潜在药物, 因此, GIP受体激动剂的筛选模型十分重要。本研究采用PCR的方法扩增GIPR基因, 将扩增产物酶切回收后与表达载体pCMV6-AC-GFP连接, 构建pCMV6-AC-GIPR-GFP重组质粒, 转化大肠杆菌DH5α经菌落扩增、质粒提取及序列测序重组质粒; 利用脂质体lipofectamine2000转染重组质粒到RIN-m5F细胞中, 通过抗生素G418筛选, 挑单克隆得到稳定的RIN-m5F/GIPR-GFP细胞株。结果: 结果表明PCR扩增获得长度为1 319 bp的GIPR基因, 克隆至pCMV6-AC-GFP真核表达载体, 经菌落PCR酶切鉴定及序列分析后, 证实质粒pCMV6-AC-GIPR-GFP构建成功; 通过荧光显微镜观察到细胞内荧光分布均匀, 表明重组质粒成功转到RIN-m5F细胞中。该细胞株经阳性对照(D-Ala2)GIP处理后, 与对照组对比, 具有荧光斑点聚集。结论: 因此, GIP受体激动剂筛选模型RIN-m5F/GIPR-GFP成功构建, 可用于筛选新的GIP受体激动剂, 为糖尿病药物开发提供新的筛选模型。
Abstract
GIP receptor agonists which can stimulate insulin secretion could be potential drugs in the treatment of type II diabetes. Therefore, it is important of the screening model for GIP receptor agonists. In this study, GIPR gene was amplified by PCR, digested by HindIII/XhoI and then connected to the expression vector pCMV6-AC-GFP to construct pCMV6-AC-GIPR-GFP recombinant plasmid. The recombinant plasmid was transformed into Escherichia coli DH5α, subsequently confirmed by colony PCR, restriction endonuclease digestion and sequencing. The recombinant plasmid was transfected into RIN-m5F cells by lipofectamine 2000. After screening with G418, the monoclonal RIN-m5F/GIPR-GFP cell line was selected. The results showed that the GIPR gene with a length of 1 319 bp was amplified and cloned into the eukaryotic expression vector of pCMV6-AC-GFP. After analysis of colony PCR, enzyme digestion and sequence, the construction of plasmid pCMV6-AC-GIPR-GFP was proved to be successful. Lots of positive puncta were observed in the treatment of GIPR agonist of (D-Ala2) GIP .The results reveal that GIPR-GFP cell line with stable expression was successfully constructed. This cell line can be used to screen agonists of GIPR for exploring potential new medicines for diabetes.
参考文献

[1] FEHER M D, BRAZIER J, SCHAPER N, et al. Patients’ with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes[J]. Bmj Open Diabetes Res Care, 2016, 4(1): e000192.

[2] SCOTTB W, SU J K, GARY K Y, et al. A GIP receptor agonist exhibits β-Cell anti-apoptotic actions in rat models of diabetes resulting in improved β-Cell function and glycemic control[J]. Plos One, 2010, 5(3): e9590.

[3] BAHTIYAR G, GUTTERMAN D, LEBOVITZ H. Heart failure: a major cardiovascular complication of diabetes mellitus[J]. Current Diabetes Reports, 2016,16(11): 116.

[4] FRIDLYAND L E, P HILIPSON L H. Pancreatic beta cell G-protein coupled receptors and second messenger interactions: asystems biology computational analysis[J]. Plos One, 2016, 11(5): e0152869.

[5] BO A. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes[J]. Nature Reviews Drug Discovery, 2009, 8(5): 369-385.

[6] 盛灵通, 孔建龙, 秦健, 等. GLP-1及其类似物治疗糖尿病的研究进展[J]. 糖尿病新世界, 2015, 22(2): 22-23.

    SHENG Tongling, KONG Jianlong, QIN Jian, et al. Research progress of GLP-1 and its analogues in the treatment of diabetes mellitus[J]. New World of Diabetes, 2015, 22(2): 22-23.

[7] NIGEL I, PETER R F. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders[J]. World Journal of Diabetes, 2015, 6(15): 1285.

[8] WANG T, MA X, TANG T, et al. The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations[J]. Nutrition & Diabetes, 2017, 7(5): e278.

[9] CARR R D, LARSEN M O, WINZELL M S, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men[J]. American Journal of Physiology Endocrinology & Metabolism, 2008, 295(4): E779.

[10] MEIER J J, GALLWITZ B, SIEPMANN N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia[J]. Diabetologia, 2003, 46(6): 798-801.

[11] MOHAMMAD S, PATEL R T, BRUNO J, et al. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity[J]. Molecular & Cellular Biology, 2014, 34(19): 3618-3629.

[12] PENG W, FIASCHITAESCH N M, VASAVADA R C, et al. Diabetes mellitus[mdash]advances and challenges in human [beta]-cell proliferation[J]. Nature Reviews Endocrinology, 2015, 11(4): 201.

[13] KAHN S E, COOPERM E, DELP S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future[J]. Lancet, 2014, 383(9922): 1068.

[14] CALANNA S, CHRISTENSEN M, HOLST J J, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies[J]. Diabetes Care, 2013, 36(10): 3346.

[15] 谢洁琼, 吕秋军, 温利青, 等. 基于报告基因和PPARγ信号通路的药物筛选模型的建立[J]. 中国药理学通报, 2005, 21(4): 504-507.

    XIE Jieqiong, LU Qiujun, WEN Liqing, et al. Development of drug screening modelbased on reporter gene and the signal transduction of PPARγ[J]. Chinese Pharmacological Bulletin,2005,21(4): 504-507.

[16] 黎思彤, 郑雪萍, 杨学敏, 等. 以 GLP-1受体为靶点的药物筛选模型的建立及功能鉴定[J]. 中国药理学通报, 2017, 33(2): 285-289.

    LI Sitong, ZHENG Xueping, YANG Xuemin, et al. Development and evaluation of a cell model targeted on GLP-1 receptor[J]. Chinese Pharmacological Bulletin, 2017, 33(2): 285-289.

[17] 曾璐漫. GLP1受体激动剂类药物筛选模型的构建[D]. 湖南农业大学, 2015.

    ZENG Luman. Construct the drug screening model for GLP-1 receptor agonists[D]. Hunan Agricultural University, 2015.

[18] 谢洁琼. 抗糖尿病药物筛选模型的建立及应用[D]. 中国人民解放军军事医学科学院, 解放军军事医学科学院, 2005.

    XIE Jieqiong. The development and application of the methods of scerening for the anti-diabetie drugs[D]. Academy of Military Medical Sciences, 2015.

[19] MARTIN C M, IWIN N, FLATTP R, et al. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores[J]. Biochimica et Biophysica Acta, 2013, 1830(6): 3407.

[20] ZHANG X, KIM K M. Multifactorial regulation of G protein-coupled receptor endocytosis[J]. Biomolecules & Therapeutics, 2017, 25(1): 26.

[21] TEITLER M, KLEIN M T. A new approach for studying GPCR dimers: drug-induced inactivation and reactivation to reveal GPCR dimer function in vitro, in primary culture, and in vivo[J]. Pharmacol Ther, 2012, 133(2): 205-217.

[22] 李胜, 白波, 陈京. G蛋白偶联受体脱敏內吞和复敏调控机制进展[J]. 济宁医学院学报, 2016, 39(2): 123-127.

    LI Sheng, BAI Bo, CHEN Jing. Regulatoty mechanisms of G protein coupled receptor about desensitization,endocytosis and resensitization[J]. Journal of Jining Medical College, 2016, 39(2): 123-127.

[23] COHEN L J, ESTERHAZY D, KIM S H, et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules[J]. Nature, 2017, 549: 48-53.

周海燕, 吴艳阳, 刘东波, 谢红旗. GIP受体激动剂类药物筛选模型的构建[J]. 激光生物学报, 2017, 26(6): 534. ZHOU Haiyan, WU Yanyang, LIU Dongbo, XIE Hongqi. Construction of Screening Model for GIP Receptor Agonists[J]. Acta Laser Biology Sinica, 2017, 26(6): 534.

关于本站 Cookie 的使用提示

中国光学期刊网使用基于 cookie 的技术来更好地为您提供各项服务,点击此处了解我们的隐私策略。 如您需继续使用本网站,请您授权我们使用本地 cookie 来保存部分信息。
全站搜索
您最值得信赖的光电行业旗舰网络服务平台!